Document is current

Article History

Received: 27 May 2025

Accepted: 2 September 2025

First Online: 28 September 2025

Declarations

:

: M.Pi. received travel support and lecture fees from Pfizer and Novartis; lecture fees from Gilead; and participated in an advisory board for Novartis. A.P.G. received lecture honoraria and travel support from AstraZeneca, Roche, Novartis, Eli Lilly, Swixx Biopharma, Gilead, and Pfizer. M.K. served on advisory boards for Novartis; received speaker’s fees and conference support from Novartis, Roche, MSD, Pfizer, Eli Lilly, Teva, Amgen, Swixx Biopharma, AstraZeneca, and Gilead; participated in clinical trials sponsored by Roche, MSD, Novartis, Seagen, and Gilead. M.L.J. declares no conflicts of interest. R.P.M. received travel support from Accord, GSK, and BMS; and lecture honoraria from BMS. P.K.V.M. declares no conflicts of interest. M.Z. received travel grants and speaker’s honoraria from Pierre Fabre, Novartis, and Ipsen. A.Ł. received honoraria and support from AstraZeneca, Pfizer, Novartis, Eli Lilly, Roche, and Gilead Sciences, including advisory board participation. M.J. received conference support from Gilead and Roche; speaker’s fees from Novartis, Roche, Eli Lilly, Pfizer, Teva, Exact Sciences, and Mammotome; and served on advisory boards for Novartis and Pfizer. M.Pu. received travel grants and lecture honoraria from AstraZeneca, Roche, Novartis, Eli Lilly, Janssen, Gilead, and Amgen.